Review on India’s Pharmaceutical Resilience: Innovations and Challengesin Global Health and the COVID-19 Era

Introduction: The global healthcare system is highly dependent on the pharmaceutical industry for uninterrupted access to medicines and vaccines, particularly during public health emergencies. Previous pandemics such as SARS, H1N1, and Ebola have shaped preparedness frameworks, with India emerging as a major global supplier of affordable generic medicines. This review critically examines the role and resilience of India’s pharmaceutical industry during global pandemics, with a focused analysis of its response to COVID-19. Methods: A narrative review was conducted using peer-reviewed articles, government reports, and international health databases published between 2000 and 2025. Sources included PubMed, Scopus, Web of Science, and Google Scholar. Documents addressing pharmaceutical manufacturing, vaccine development, supply chains, and policy interventions during pandemics were included. A qualitative thematic framework was employed to extract and synthesize data on manufacturing capacity, exports, regulatory responses, innovation, and digital health integration. Results: India’s pharmaceutical industry showed strong resilience during COVID-19, ensuring large-scale production and global supply of medicines and vaccines, including Covaxin and Covishield. Strategic private partnerships, regulatory flexibility, and advances in biotechnology strengthened national manufacturing capacity. Nonetheless, challenges related to equitable access, pricing controls, supply chain vulnerabilities, and ethical marketing remain. Discussion: India's pharmaceutical industry demonstrated remarkable strength by producing many vaccines and exporting more, solidifying its position as the pharmacy of the world. However, this success also showed major weaknesses, such as a heavy reliance on imported active pharmaceutical ingredients (62% from China before the pandemic). Regulatory flexibility and Production Linked Incentive programs have helped domestic manufacturing, but there are still problems with fair access, supply chain resilience, and disparities in healthcare infrastructure. To maintain global leadership, dependence on imports must be reduced, strong regulatory frameworks should be established, and pandemic preparedness should be strengthened through major structural reforms. Conclusion: India’s pharmaceutical sector has consolidated its position as a global health contributor during pandemics. Sustained leadership in the post-pandemic era will depend on continued innovation, robust regulatory frameworks, sustainable manufacturing practices, and strengthened healthcare infrastructure.